Table 1.
Patient Characteristics
| Demographics | ||
| Year | (IQR) | |
| Median Age | 68 | (65–75) |
| Race | % | (N) |
| Black | 31.0 | 9 |
| Asian | 6.9 | 2 |
| White | 62.1 | 18 |
| Clinical | # | (IQR) |
| Median PSA (ng/nL) | 13.5 | (7.47–32.45) |
| Median MRI tumor burden (cm3) | 2.52 | (1.14–6.86) |
| NCCN Risk Group | % | (N) |
| Favorable intermediate | 6.9 | 2 |
| Unfavorable intermediate | 13.8 | 4 |
| High | 24.1 | 7 |
| Very high | 55.2 | 16 |
| Histology | ||
| Clinical stage | % | (N) |
| T1c | 44.8 | 13 |
| T2 | 20.7 | 6 |
| T3a | 17.2 | 5 |
| T3b | 17.2 | 5 |
| Gleason score (grade group) | % | (N) |
| 3+4 (2) | 10.3 | 3 |
| 4+3 (3) | 10.3 | 3 |
| 4+4; 3+5; 5+3 (4) | 37.9 | 11 |
| 4+5; 5+4; 5+5 (5) | 41.4 | 12 |
| Treatment | % | (N) |
| ADT use | 93.1% | 27 |
| Pelvic lymph node radiation | 89.7% | 26 |
| # | range | |
| Median EBRT dose | 7920 cGy | 7560–7920 cGy |
| Median ADT duration | 28 months | 6–36 months |